ClinicalTrials.gg
CompletedNCT05879107Updated May 18, 2025Results posted

Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

A Phase 3 interventional study of RSVPreF3 OA investigational vaccine and PCV20 in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 38 sites in 4 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,113
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline — 1 open to participants now, 5 under way, 3 of them phase 3. Respiratory Syncytial Virus Infections · GlaxoSmithKline.

Enrollment
12th of 40
1,113 · median 642
Started
2023
with 3 others
Phase 3
21 of 40
none open now
Registered
29th of 40
by date

Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 12th largest by enrollment, is one of 4 that started in 2023, is one of 21 in phase 3, and was the 29th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with PCV20 and its safety in older adults, aged ≥60 years of age.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory syncytial virus
  • Vaccine
  • Older adult
  • Immunogenicity
  • Safety
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A male or female ≥60 years of age at the time of the first study intervention administration.
  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written or witnessed obtained from the participant prior to any study-specific procedure being performed.
  • Participants living in the general community or in an assisted-living facility that provides minimal assistance, such that the participant is primarily responsible for self care and activities of daily living.
  • Participants who are medically stable in the opinion of the investigator at the time of first study intervention administration. Participants with chronic stable medical conditions with or without specific treatment, are allowed to participate in this study if considered by the investigator as medically stable.

Exclusion criteria

Exclusion Criteria:

  • Any confirmed or suspected or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history and physical examination.
  • History of any reaction or likely to be exacerbated by the study interventions, in particular any history of severe allergic reaction to any vaccine containing diphtheria toxoid, or pneumococcal polysaccharide 23-valent vaccine (PPSV23).
  • Participants considered by investigator as suffering from serious or unstable chronic illness.
  • Any history of dementia or any medical condition that moderately or severely impairs cognition.
  • Recurrent or uncontrolled neurological disorders or seizures. Participants with medically controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol.
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
  • History of previous vaccination with any licensed or pneumococcal conjugate vaccine, or planned receipt through study participation.
  • History of previous vaccination with any licensed or investigational pneumococcal polysaccharide vaccine in the last 5 years from enrollment, or planned receipt through study participation.
  • Previous vaccination with any licensed or investigational RSV vaccine
  • Use of any investigational or non-registered product (drug, vaccine or medical device) other than the study interventions during the period beginning 30 days before the first dose of study interventions and ending 30 days after the last study intervention administration, or their planned use during the study period.
  • Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first study intervention administration and ending 30 days after the last study intervention administration. In the case of COVID 19 and inactivated/subunit influenza vaccines, this time window can be decreased to 14 days before and after each study intervention administration. In case of COVID-19 vaccine administration within 14 to 30 days window, the administration of COVID-19 vaccine should be in accordance with local government recommendations.

    • Planned or actual administration of adjuvanted quadrivalent influenza vaccine or live influenza vaccine not foreseen by the study protocol in the period starting 30 days before the first study intervention administration and ending 30 days after the last study intervention administration.

Note: In case an emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and/or organized by the public health authorities outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine, provided it is used according to the local governmental recommendations and that the Sponsor or designee is notified accordingly.

  • Administration of long-acting immune-modifying drugs or planned administration at any time during the study period.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the administration of first dose of study interventions or planned administration during the study period.
  • Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first study intervention dose or planned administration during the study period. For , this will mean prednisone ≥20 mg/day, or equivalent. Inhaled and topical steroids are allowed.
  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or invasive medical device).
  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
  • Bedridden participants.
  • Planned move during the study conduct that prohibits participation until EoS.
  • Participation of any study personnel or their immediate dependents, family, or household members.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,113 participants (actual)

Study arms

  • Experimental
    Co-administration Group

    Participants received both respiratory syncytial virus prefusion protein 3 older adult (RSVPreF3 OA) vaccine and 20-valent pneumococcal conjugate vaccine (PCV20) on Day 1.

    Biological: RSVPreF3 OA investigational vaccine · Biological: PCV20

  • Active comparator
    Control Group

    Participants received PCV20 vaccine on Day 1 and RSVPreF3 OA vaccine on Day 31.

    Biological: RSVPreF3 OA investigational vaccine · Biological: PCV20

Interventions

  • One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).

    Also known as: RSVPreF3 OA

  • BiologicalPCV20

    One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1

    Also known as: 20 valent pneumococcal vaccine, Prevnar 20 (in US), Apexxnar (in Europe)

06

What researchers measure

Primary outcomes

  1. Adjusted Geometric Mean Titers (GMT) of Opsonophagocytic (OP) Titers at 1 Month After the PCV20 Vaccination

    The OP titers were measured with multiplexed opsonophagocytosis assay and the results were expressed as GMT for each of the pneumococcal vaccine serotype.

    Time frame: At Day 31

  2. Adjusted GMTs of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers [Estimated Dilution 60 (ED60)] at 1 Month After the RSVPreF3 OA Vaccination

    Neutralizing titers were measured with neutralization assay and the results were expressed in ED60.

    Time frame: At Day 31 for Co-administration Group and at Day 61 for Control Group

  3. Adjusted GMTs of RSV-B Neutralizing Titers (ED60) at 1 Month After the RSVPreF3 OA Vaccination

    Neutralizing titers were measured with neutralization assay and the results were expressed in ED60.

    Time frame: At Day 31 for Co-administration Group and at Day 61 for Control Group

Secondary outcomes

  1. Mean Geometric Increase (MGI) of RSV-A Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination

    The MGI was defined as the geometric mean increase of the within participant ratios of the post-vaccination titer over the pre-vaccination titer. Neutralizing titers were measured with neutralization assay.

    Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for Co-administration Group and Day 61 for Control Group) compared to Pre-vaccination (Day 1 for Co-administration Group and Day 31 for Control Group)

  2. MGI of RSV-B Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination

    The MGI was defined as the geometric mean increase of the within participant ratios of the post-vaccination titer over the pre-vaccination titer. Neutralizing titers were measured with neutralization assay.

    Time frame: At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for Co-administration Group and Day 61 for Control Group) compared to Pre-vaccination (Day 1 for Co-administration Group and Day 31 for Control Group)

  3. Number of Participants With Solicited Administration Site Adverse Events (AEs) After Each Vaccine Dose Administration

    The solicited administration site events after vaccination include pain, erythema/redness, and swelling.

    Time frame: Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine administration (vaccines administered at Day 1 for Co-Administration Group and at Days 1 and 31 for Control group)

  4. Number of Participants With Solicited Systemic AEs After Each Vaccine Dose Administration

    The solicited systemic events after vaccination include fever (pyrexia), headache, fatigue, myalgia and arthralgia. Fever is defined as body temperature \>=38 degree Celsius; preferred location for measuring the temperature is oral.

    Time frame: Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine administration (vaccines administered at Day 1 for Co-Administration Group and at Days 1 and 31 for Control group)

  5. Number of Participants With Unsolicited AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the administration of a study vaccine, which does not necessarily have a causal relationship with study vaccine. An unsolicited AE is an AE that is either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs are communicated by participant/participant's caregiver(s) who have signed the informed consent. Unsolicited AEs include both serious adverse events (SAEs) and non-serious AEs.

    Time frame: Within 30 days (the day of vaccination and 29 subsequent days) after each vaccine administration (vaccines administered at Day 1 for Co-Administration Group and at Days 1 and 31 for Control group)

  6. Number of Participants With SAEs

    An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

    Time frame: Throughout the study period (from Day 1 up to 6 months after the last dose administration [last dose given at Day 1 for Co-administration Group and Day 31 for Control Group])

  7. Number of Participants With Potential Immune-mediated Diseases (pIMDs)

    The pIMD is a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

    Time frame: Throughout the study period (from Day 1 up to 6 months after the last dose administration [last dose given at Day 1 for Co-administration Group and Day 31 for Control Group])

07

Results

Posted May 18, 2025

Participant flow

This study was conducted in adult participants aged 60 years and older, in 38 study sites.

Participant flow — Overall Study
MilestoneCo-administration GroupControl Group
Started553557
Completed539531
Not completed1426
Withdrew: Withdrawal by participant, not due to an adverse event57
Withdrew: Migrated / moved from the study area11
Withdrew: Lost to follow-up813
Withdrew: Death02
Withdrew: Other03

Outcome measures

PrimaryAdjusted Geometric Mean Titers (GMT) of Opsonophagocytic (OP) Titers at 1 Month After the PCV20 Vaccination

The OP titers were measured with multiplexed opsonophagocytosis assay and the results were expressed as GMT for each of the pneumococcal vaccine serotype.

Time frame:
At Day 31
Reported as:
Geometric mean · Titers
Adjusted Geometric Mean Titers (GMT) of Opsonophagocytic (OP) Titers at 1 Month After the PCV20 Vaccination
TitersCo-administration GroupControl Group
Strep pneumoniae - serotype 174.7 (64.1 to 87.1)110.8 (94.8 to 129.5)
Strep pneumoniae - serotype 388.5 (78.3 to 99.9)116.2 (102.7 to 131.5)
Strep pneumoniae - serotype 41220.9 (1072.9 to 1389.3)1634.1 (1433.4 to 1862.8)
Strep pneumoniae - serotype 5191.0 (159.9 to 228.1)260.3 (217.3 to 311.8)
Strep pneumoniae - serotype 6A1790.0 (1527.8 to 2097.2)2458.3 (2091.8 to 2889.1)
Strep pneumoniae - serotype 6B2121.6 (1839.0 to 2447.6)2996.9 (2590.3 to 3467.2)
Strep pneumoniae - serotype 7F2411.3 (2154.1 to 2699.2)3225.1 (2876.2 to 3616.4)
Strep pneumoniae - serotype 8522.9 (458.5 to 596.4)723.0 (632.5 to 826.5)
Strep pneumoniae - serotype 9V937.0 (822.3 to 1067.8)1161.0 (1016.7 to 1325.8)
Strep pneumoniae - serotype 10A6033.4 (5299.5 to 6868.9)7349.4 (6437.8 to 8389.9)
Strep pneumoniae - serotype 11A798.0 (691.5 to 921.0)944.2 (816.9 to 1091.5)
Strep pneumoniae - serotype 12F1608.4 (1382.9 to 1870.8)1932.4 (1656.5 to 2254.3)
Strep pneumoniae - serotype 142322.3 (2050.5 to 2630.1)3301.4 (2909.1 to 3746.7)
Strep pneumoniae - serotype 15B4336.4 (3765.8 to 4993.5)6350.2 (5500.4 to 7331.3)
Strep pneumoniae - serotype 18C1148.6 (997.6 to 1322.5)1480.0 (1282.4 to 1708.0)
Strep pneumoniae - serotype 19A1392.3 (1244.3 to 1557.8)1933.8 (1725.2 to 2167.7)
Strep pneumoniae - serotype 19F525.6 (461.6 to 598.5)696.7 (610.6 to 794.9)
Strep pneumoniae - serotype 22F5492.3 (4788.1 to 6300.1)7351.5 (6397.0 to 8448.5)
Strep pneumoniae - serotype 23F729.7 (613.0 to 868.6)995.0 (832.8 to 1188.7)
Strep pneumoniae - serotype 33F14902.8 (13220.7 to 16798.8)20920.9 (18526.9 to 23624.3)
Statistical analysis
  • Co-administration Group vs Control Group · Gmt ratio: 1.48 · 95% CI 1.22 to 1.81The analysis of covariance (ANCOVA) model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.31 · 95% CI 1.12 to 1.54The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.34 · 95% CI 1.13 to 1.58The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.36 · 95% CI 1.08 to 1.71The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.37 · 95% CI 1.12 to 1.69The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.41 · 95% CI 1.17 to 1.70The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.34 · 95% CI 1.16 to 1.55The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.38 · 95% CI 1.17 to 1.64The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.24 · 95% CI 1.05 to 1.47The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.22 · 95% CI 1.03 to 1.44The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.18 · 95% CI 0.98 to 1.42The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.20 · 95% CI 0.99 to 1.46The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.42 · 95% CI 1.21 to 1.67The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.46 · 95% CI 1.22 to 1.76The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.29 · 95% CI 1.07 to 1.55The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.39 · 95% CI 1.20 to 1.61The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.33 · 95% CI 1.12 to 1.57The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.34 · 95% CI 1.12 to 1.60The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.36 · 95% CI 1.09 to 1.71The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
  • Co-administration Group vs Control Group · Gmt ratio: 1.40 · 95% CI 1.20 to 1.64The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
PrimaryAdjusted GMTs of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers [Estimated Dilution 60 (ED60)] at 1 Month After the RSVPreF3 OA Vaccination

Neutralizing titers were measured with neutralization assay and the results were expressed in ED60.

Time frame:
At Day 31 for Co-administration Group and at Day 61 for Control Group
Reported as:
Geometric mean · Titers
Adjusted GMTs of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers [Estimated Dilution 60 (ED60)] at 1 Month After the RSVPreF3 OA Vaccination
TitersCo-administration GroupControl Group
Adjusted GMTs of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers [Estimated Dilution 60 (ED60)] at 1 Month After the RSVPreF3 OA Vaccination8338.2 (7639.0 to 9101.4)8872.7 (8038.2 to 9793.9)
Statistical analysis
  • Co-administration Group vs Control Group · Gmt ratio: 1.06 · 95% CI 0.94 to 1.20The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
PrimaryAdjusted GMTs of RSV-B Neutralizing Titers (ED60) at 1 Month After the RSVPreF3 OA Vaccination

Neutralizing titers were measured with neutralization assay and the results were expressed in ED60.

Time frame:
At Day 31 for Co-administration Group and at Day 61 for Control Group
Reported as:
Geometric mean · Titers
Adjusted GMTs of RSV-B Neutralizing Titers (ED60) at 1 Month After the RSVPreF3 OA Vaccination
TitersCo-administration GroupControl Group
Adjusted GMTs of RSV-B Neutralizing Titers (ED60) at 1 Month After the RSVPreF3 OA Vaccination9477.5 (8695.4 to 10329.9)9497.6 (8620.5 to 10463.9)
Statistical analysis
  • Co-administration Group vs Control Group · Gmt ratio: 1.00 · 95% CI 0.89 to 1.13The ANCOVA model, for logarithm-transformed titers, included the treatment group and age category at vaccination as fixed effects and the pre-dose log-10 titer as covariate.
SecondaryMean Geometric Increase (MGI) of RSV-A Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination

The MGI was defined as the geometric mean increase of the within participant ratios of the post-vaccination titer over the pre-vaccination titer. Neutralizing titers were measured with neutralization assay.

Time frame:
At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for Co-administration Group and Day 61 for Control Group) compared to Pre-vaccination (Day 1 for Co-administration Group and Day 31 for Control Group)
Reported as:
Geometric mean · Ratio
Mean Geometric Increase (MGI) of RSV-A Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination
RatioCo-administration GroupControl Group
Mean Geometric Increase (MGI) of RSV-A Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination8.3 (7.6 to 9.1)9.3 (8.3 to 10.3)
SecondaryMGI of RSV-B Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination

The MGI was defined as the geometric mean increase of the within participant ratios of the post-vaccination titer over the pre-vaccination titer. Neutralizing titers were measured with neutralization assay.

Time frame:
At 1 month after the RSVPreF3 OA vaccine dose (Day 31 for Co-administration Group and Day 61 for Control Group) compared to Pre-vaccination (Day 1 for Co-administration Group and Day 31 for Control Group)
Reported as:
Geometric mean · Ratio
MGI of RSV-B Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination
RatioCo-administration GroupControl Group
MGI of RSV-B Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination9.4 (8.6 to 10.2)9.1 (8.2 to 10.1)
SecondaryNumber of Participants With Solicited Administration Site Adverse Events (AEs) After Each Vaccine Dose Administration

The solicited administration site events after vaccination include pain, erythema/redness, and swelling.

Time frame:
Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine administration (vaccines administered at Day 1 for Co-Administration Group and at Days 1 and 31 for Control group)
Reported as:
Count of participants · Participants
Number of Participants With Solicited Administration Site Adverse Events (AEs) After Each Vaccine Dose Administration
ParticipantsCo-administration GroupControl Group
Pain at injection site, PCV20 dose, given at Day 1283208
Pain at injection site, RSV dose, given at Day 1290—
Pain at injection site, RSV dose, given at Day 31—225
Erythema at injection site, PCV20 dose, given at Day 12421
Erythema at injection site, RSV dose, given at Day 154—
Erythema at injection site, RSV dose, given at Day 31—33
Swelling at injection site, PCV20 dose, given at Day 11717
Swelling at injection site, RSV dose, given at Day 126—
Swelling at injection site, RSV dose, given at Day 31—21
SecondaryNumber of Participants With Solicited Systemic AEs After Each Vaccine Dose Administration

The solicited systemic events after vaccination include fever (pyrexia), headache, fatigue, myalgia and arthralgia. Fever is defined as body temperature \>=38 degree Celsius; preferred location for measuring the temperature is oral.

Time frame:
Within 7 days (the day of vaccination and 6 subsequent days) after each vaccine administration (vaccines administered at Day 1 for Co-Administration Group and at Days 1 and 31 for Control group)
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic AEs After Each Vaccine Dose Administration
ParticipantsCo-administration GroupControl Group
Fever, Dosing at Day 1164
Fever, Dosing at Day 31—8
Headache, Dosing at Day 114483
Headache, Dosing at Day 31—97
Fatigue, Dosing at Day 1198152
Fatigue, Dosing at Day 31—144
Myalgia, Dosing at Day 117689
Myalgia, Dosing at Day 31—108
Arthralgia, Dosing at Day 18041
Arthralgia, Dosing at Day 31—67
SecondaryNumber of Participants With Unsolicited AEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the administration of a study vaccine, which does not necessarily have a causal relationship with study vaccine. An unsolicited AE is an AE that is either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs are communicated by participant/participant's caregiver(s) who have signed the informed consent. Unsolicited AEs include both serious adverse events (SAEs) and non-serious AEs.

Time frame:
Within 30 days (the day of vaccination and 29 subsequent days) after each vaccine administration (vaccines administered at Day 1 for Co-Administration Group and at Days 1 and 31 for Control group)
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited AEs
ParticipantsCo-administration GroupControl Group
Number of Participants With Unsolicited AEs6098
SecondaryNumber of Participants With SAEs

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

Time frame:
Throughout the study period (from Day 1 up to 6 months after the last dose administration [last dose given at Day 1 for Co-administration Group and Day 31 for Control Group])
Reported as:
Count of participants · Participants
Number of Participants With SAEs
ParticipantsCo-administration GroupControl Group
Number of Participants With SAEs914
SecondaryNumber of Participants With Potential Immune-mediated Diseases (pIMDs)

The pIMD is a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

Time frame:
Throughout the study period (from Day 1 up to 6 months after the last dose administration [last dose given at Day 1 for Co-administration Group and Day 31 for Control Group])
Reported as:
Count of participants · Participants
Number of Participants With Potential Immune-mediated Diseases (pIMDs)
ParticipantsCo-administration GroupControl Group
Number of Participants With Potential Immune-mediated Diseases (pIMDs)21

Adverse events

Collected over Solicited AEs were collected up to Day 7 post each vaccination. Unsolicited AEs were collected up to Day 30 post each vaccination. SAEs and pIMDs were collected throughout the study period from Day 1 up to 6 months post last vaccination.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Co-administration Group0/553 (0%)9/553 (1.6%)410/553 (74.1%)
Control Group2/557 (0.4%)14/557 (2.5%)423/557 (75.9%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventCo-administration GroupControl Group
DeathGeneral disorders0/5532/557
PneumoniaInfections and infestations0/5532/557
Supraventricular tachycardiaCardiac disorders1/5530/557
Small intestinal obstructionGastrointestinal disorders1/5530/557
Pneumonia bacterialInfections and infestations1/5530/557
Fracture displacementInjury, poisoning and procedural complications1/5530/557
FallInjury, poisoning and procedural complications1/5530/557
OsteoarthritisMusculoskeletal and connective tissue disorders1/5530/557
Breast cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps)1/5530/557
DizzinessNervous system disorders1/5530/557
Most frequent other events
Showing 10 of 112
Most frequent other events
EventCo-administration GroupControl Group
Injection site painGeneral disorders337/553312/557
FatigueGeneral disorders198/553217/557
MyalgiaMusculoskeletal and connective tissue disorders176/553157/557
HeadacheNervous system disorders144/553142/557
ArthralgiaMusculoskeletal and connective tissue disorders80/55394/557
Injection site erythemaGeneral disorders64/55348/557
Injection site swellingGeneral disorders38/55338/557
PyrexiaGeneral disorders18/55313/557
COVID-19Infections and infestations1/55311/557
Upper respiratory tract infectionInfections and infestations1/5537/557

Baseline characteristics

Exposed set included all participants in the Enrolled set who received at least 1 study intervention.

Age, Continuous
Age, Continuous(years)Co-administration GroupControl GroupTotal
Mean69.6 ± 7.2869.6 ± 7.4169.6 ± 7.35
Sex: Female, Male
Sex: Female, Male(Participants)Co-administration GroupControl GroupTotal
Female316315631
Male237242479
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Co-administration GroupControl GroupTotal
Black or African American6454118
All Other Races7714
White476488964
Multiple246
Other448
08

Study locations

38 sites
  • GSK Investigational Site
    Guntersville, Alabama 35976, United States
  • GSK Investigational Site
    Phoenix, Arizona 85023, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Modesto, California 95350, United States
  • GSK Investigational Site
    Hamden, Connecticut 06517, United States
  • GSK Investigational Site
    Clearwater, Florida 33756, United States
  • GSK Investigational Site
    DeLand, Florida 32720, United States
  • GSK Investigational Site
    Jupiter, Florida 33458, United States
  • GSK Investigational Site
    Largo, Florida 33777, United States
  • GSK Investigational Site
    Orlando, Florida 32801, United States
  • GSK Investigational Site
    West Des Moines, Iowa 50266, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70115, United States
  • GSK Investigational Site
    Troy, Michigan 48085, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63110, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45212, United States
  • GSK Investigational Site
    North Charleston, South Carolina 29405, United States
  • GSK Investigational Site
    Dallas, Texas 75251, United States
  • GSK Investigational Site
    Frisco, Texas 75033, United States
  • GSK Investigational Site
    Mesquite, Texas 75149, United States
  • GSK Investigational Site
    Plano, Texas 75024, United States
  • GSK Investigational Site
    Antwerpen, 2000, Belgium
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Kluisbergen, 9690, Belgium
  • GSK Investigational Site
    Mechelen, 2800, Belgium
  • GSK Investigational Site
    Namur, 5000, Belgium
  • GSK Investigational Site
    Wetteren, 9230, Belgium
  • GSK Investigational Site
    KrakOw, 31-501, Poland
  • GSK Investigational Site
    Lodz, 91-363, Poland
  • GSK Investigational Site
    Lublin, 20-362, Poland
  • GSK Investigational Site
    Pu?awy, 24-100, Poland
  • GSK Investigational Site
    Staszow, 28-200, Poland
  • GSK Investigational Site
    Warsaw, 03-291, Poland
  • GSK Investigational Site
    Warszawa, 00-215, Poland
  • GSK Investigational Site
    Warszawa, 02-677, Poland
  • GSK Investigational Site
    Wroclaw, 53-673, Poland
  • GSK Investigational Site
    Barcelona, 08023, Spain
  • GSK Investigational Site
    Barcelona, 8025, Spain
  • GSK Investigational Site
    Valencia, 46020, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer tohttps://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Dec 2023, 6 months.

Results were first posted in May 2025, 1 year 5 months after primary completion. A results delay was requested in Dec 2024.

Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 6 months is below that.

Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2023
First posted
May 30, 2023
StartActual
May 26, 2023
Primary completionActual
Dec 6, 2023
CompletionActual
May 7, 2024
Results delay requested
Dec 3, 2024
Results first posted
May 18, 2025
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05879107
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 30, 2023
Start date
May 26, 2023
Primary completion
Dec 6, 2023
Completion
May 7, 2024
Results posted
May 18, 2025
Last update
May 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion